STENTYS: Financial Information for the First Quarter Of 2020
15 Maggio 2020 - 5:45PM
Business Wire
- Q1 2020 consolidated revenues of €0.8 million
- Liquidation of the Group’s inventories
- Consolidated cash position of €6.1 million at March 31,
2020
Regulatory News:
STENTYS (Paris:STNT) (FR0010949404 – STNT), a French
group specialized in medical technologies for interventional
cardiology, today reported its consolidated quarterly revenues and
cash position at March 31, 2020.
First-quarter revenues by geographical region
€ thousands
Q1 2020
Q1 2019
% change
Europe1
442
1,357
-67%
Rest of the world
315
1,243
-75%
Total revenues
757
2,600
-71%
Audited data
First-quarter revenues by product category
€ thousands
Q1 2020
Q1 2019
% change
Stents
133
1,638
-92%
Balloons & accessories
624
961
-35%
Total revenues
757
2,600
-71%
Audited data
During the first quarter of 2020, the Company liquidated its
inventories. On the date of publication of this press release, the
Company no longer has regulatory clearance to market its products.
Unsold products have been destroyed. STENTYS will henceforth
generate no further revenues.
Cash position of €6.1 million The Group had a cash
position of €6.1 million at March 31, 2020 versus €8.2 million at
December 31, 2019.
Additional information is available at
www.stentys.com.
STENTYS is listed on Compartment C of Euronext Paris ISIN:
FR0010949404 – Ticker: STNT
***
Forward-looking statements
This press release contains forward-looking statements about the
Company that are based on numerous assumptions regarding the
Company’s present and future business strategies and the
environment in which it will operate in the future which may not be
accurate. Such forward-looking statements involve known and unknown
risks which may cause the Company’s actual results, performance or
achievements to differ materially from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others,
risks associated with the development and commercialization of the
Company’s products, market acceptance of the Company’s products,
its ability to manage growth, the competitive environment in
relation to its business area and markets, its ability to enforce
and protect its patents and proprietary rights, uncertainties
related to the U.S. FDA approval process, slower than expected
rates of patient recruitment for clinical trials, the outcome of
clinical trials, and other factors, including those described in
the Section 4 “Risk Factors” of the Company’s 2016 Registration
Document (document de référence) filed with the French Autorité des
Marchés Financiers (AMF) on November 29, 2017 under number
D.17-1084.
-------------------------------
1Gerrmany, Italy, Switzerland, Austria, Poland, Netherlands,
France, Belgium, United Kingdom, Spain, Greece, Portugal and Nordic
countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200515005391/en/
STENTYS André Lerebours CFO Tel.: +33 (0)1 44 53 99 42
investor@stentys.com
NewCap Investor Relations / Strategic Communications
Dusan Oresansky / Pierre Laurent Tel.: +33 (0)1 44 71 94 92
stentys@newcap.eu